Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ocular immune privilege and CTL tolerance.

Kyle C McKenna1, Judith A Kapp

  • 1Department of Ophthalmology, Emory University Medical School, 1365 Clifton Road NE, Atlanta, GA 30322, USA..

Immunologic Research
|June 8, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Validation of Ethical COVID-19 Antibody Testing that Adheres to Pro-Life Principles.

The Linacre quarterly·2024
Same author

Comment on "γδ T Cells Are Required for the Induction of Sterile Immunity during Irradiated Sporozoite Vaccinations".

Journal of immunology (Baltimore, Md. : 1950)·2018
Same author

Splenectomy restores tumoricidal activity to promote elimination of intraocular tumors.

Oncoimmunology·2015
Same author

Splenectomy promotes indirect elimination of intraocular tumors by CD8+ T cells that is associated with IFNγ- and Fas/FasL-dependent activation of intratumoral macrophages.

Cancer immunology research·2014
Same author

Biology of advanced uveal melanoma and next steps for clinical therapeutics.

Pigment cell & melanoma research·2014
Same author

S100A8/A9 proteins mediate neutrophilic inflammation and lung pathology during tuberculosis.

American journal of respiratory and critical care medicine·2013
Same journal

Emapalumab plus conventional therapy with or without ruxolitinib for pediatric hemophagocytic lymphohistiocytosis: a single center retrospective study.

Immunologic research·2026
Same journal

Immunological spectrum in patients with thymoma: beyond good syndrome.

Immunologic research·2026
Same journal

Microbiome immune crosstalk in Sjögren's syndrome: mechanistic insights and translational perspectives.

Immunologic research·2026
Same journal

Immune checkpoint inhibitor-induced myasthenia gravis and myocarditis: a fatal immune-related adverse event.

Immunologic research·2026
Same journal

TRIM28 and TRIM32: multifaceted regulators of innate immunity and antiviral defence.

Immunologic research·2026
Same journal

Decoding PANoptosis: Crosstalk of cell death pathways in immunity and inflammation.

Immunologic research·2026
See all related articles

Introducing antigens into the eye's anterior chamber (AC) triggers immune responses that protect against pathogens while preventing blindness. This process, AC associated immune deviation (ACAID), balances immune function and ocular tissue preservation.

Area of Science:

  • Ophthalmology
  • Immunology
  • Cellular Biology

Background:

  • The anterior chamber (AC) of the eye is an immune-privileged site.
  • Immune responses in the AC, known as AC associated immune deviation (ACAID), protect the eye from pathogens while minimizing damage.
  • ACAID is an evolutionary mechanism to preserve ocular microanatomy and function.

Purpose of the Study:

  • To compare and contrast cytotoxic T lymphocyte (CTL) responses induced by soluble antigens versus tumor-associated antigens in the AC.
  • To discuss the mechanisms underlying ocular CTL tolerance induced by ACAID.

Main Methods:

  • Review of existing literature on immune responses in the anterior chamber of the eye.
  • Comparison of systemic immune tolerance (reduced delayed-type hypersensitivity) and CTL responses following AC antigen administration.

Related Experiment Videos

  • Analysis of the efficacy of ACAID-induced CTLs in eliminating ocular tumors versus systemic tumor challenges.

    • Main Results:

    • Injection of soluble antigens into the AC induces systemic tolerance, reducing delayed-type hypersensitivity (DTH) and CTL responses.
    • Administration of allogeneic tumors into the AC reduces DTH responses but induces robust systemic CTL responses capable of eliminating subsequent tumor challenges.
    • CTL responses generated by AC tumor administration fail to eliminate the primary ocular tumor, indicating localized immune suppression.

    Conclusions:

    • ACAID induces distinct systemic immune outcomes depending on the nature of the antigen (soluble vs. tumor-associated).
    • While ACAID can promote systemic anti-tumor immunity, it also establishes local immune tolerance within the eye.
    • Understanding these mechanisms is crucial for developing effective immunotherapies for ocular diseases and cancers.